在帕金森病中的多巴反应
Sacha E Gandhi1, Anahita Nodehi2, Michael A Lawton2
1School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.
Movement disorders clinical practice
|June 20, 2024
概括
帕金森病 (PD) 中的多巴胺反应模式随着时间的推移而演变,随着疾病持续时间的增加,明确的反应会增加. 早期治疗反应可能不是PD的可靠诊断指标.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多巴胺反应反应是帕金森病 (PD) 的标志.
- 了解PD中多巴胺反应的时间演变至关重要.
- 关于多巴胺激应反应在PD过程中如何改变的数据有限.
研究的目的:
- 为了研究帕金森病中多巴胺反应的纵向模式.
- 随着时间的推移,识别不同的多巴胺反应集群.
- 确定预测这些已识别的响应模式的因素.
主要方法:
- 来自帕金森氏症进展标志物倡议 (PPMI) 的反复多巴胺激素挑战测试的分析.
- 使用增长混合模型来确定不同的纵向反应轨迹.
- 用多项逻辑回归来确定这些响应集群的预测因素.
主要成果:
- 总共分析了来自336名PD患者的1525个多巴胺激素挑战测试.
- 确定的多巴胺反应的比例 (≥24.5%) 随着疾病持续时间的延长而增加 (48.0%在1-2年以后达到74.3%).
- 确定了三个不同的响应组:引人注目的 (8.7%),优秀的 (32.7%) 和适度的 (58.6%),具有不同的临床和认知特征.
结论:
- 在帕金森病中观察到三种不同的多巴胺反应纵向模式.
- 随着时间的推移,明确的多巴胺反应反应的普及率越来越高,这表明其作为早期诊断标记物的实用性可能有限.
- 临床和认知因素区分了已识别的响应组,提供了对疾病异质性的见解.
相关概念视频
01:24Parkinson's Disease: Treatment
255
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
255
01:15Parkinson's Disease: Overview
524
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
524
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
305
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
305
01:03Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K